Register for our free email digests:
Andrew McConaghie
Senior Writer
Andrew is a London-based journalist who has been writing about pharma, biotech and healthcare for over 20 years.
He writes on a range of topics, including biopharma R&D and commercial issues, digital healthcare and issues affecting patients and global healthcare systems, especially the UK’s NHS.
Latest From Andrew McConaghie
More Encouraging Real World Data From UK – But Can It Turn Around European Sentiment On AZ COVID-19 Vaccine?
Another real-world study from the UK’s rapid vaccine rollout provides evidence that Pfizer’s vaccine saves lives, with the AZ shot matching it on cutting hospitalizations.
Novavax Sets Out Vaccine Strategy For New COVID-19 Variants
The US company is poised to file with regulators in Q2, but is also looking for longer-term competitive advantage in its variant strategy.
EU Resets Industry Relations In Pursuit Of Summer COVID-19 Vaccination Goal
The EU has just become the world’s biggest buyer of COVID-19 vaccines – and wants to make that purchasing power count in 2021 and beyond.
Roche Gets Long-Awaited Green Light For COVID-19 Cocktail In EU
Key committee was asked to fast-track a decision on the antibody cocktail, but lack of mortality data could mean patchy uptake seen in US repeated in the EU.
COVID-19 Vaccine Gives Moderna $18bn Launchpad Into HIV Vaccine, Cancer Therapies
A rush of additional orders from countries around the world has boosted the company’s prospects, and fueled its ambitions beyond COVID-19.
CEOs Face Grilling On Vaccine Supply In EU
AstraZeneca's CEO and other leaders from COVID-19 vaccine companies will face some tough questions in Brussels, but the European Commission wants to put differences behind it and solve the vaccine supply problem as soon as possible.